These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 35367199)

  • 1. Kaplan-Meier Survival, Actuarial Survival, Censoring, and Competing Events-What Is What?
    Hage A; Hage F
    Ann Thorac Surg; 2022 Jul; 114(1):40-43. PubMed ID: 35367199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Considerations for analysis of time-to-event outcomes subject to competing risks in veterinary clinical studies.
    Oyama MA; Shaw PA; Ellenberg SS
    J Vet Cardiol; 2018 Jun; 20(3):143-153. PubMed ID: 29680637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Understanding survival analysis: actuarial life tables and the Kaplan-Meier plot.
    Barakat A; Mittal A; Ricketts D; Rogers BA
    Br J Hosp Med (Lond); 2019 Nov; 80(11):642-646. PubMed ID: 31707885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced considerations in survival analysis.
    Carnero-Alcázar M; Montero-Cruces L; Cobiella-Carnicer J; Pérez-Camargo D; Maroto Castellanos L
    Eur J Cardiothorac Surg; 2024 Feb; 65(2):. PubMed ID: 38244566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis.
    Schuster NA; Hoogendijk EO; Kok AAL; Twisk JWR; Heymans MW
    J Clin Epidemiol; 2020 Jun; 122():42-48. PubMed ID: 32165133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Competing risk bias was common in Kaplan-Meier risk estimates published in prominent medical journals.
    van Walraven C; McAlister FA
    J Clin Epidemiol; 2016 Jan; 69():170-3.e8. PubMed ID: 26232083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kaplan-Meier curves for survivor causal effects with time-to-event outcomes.
    Chiba Y
    Clin Trials; 2013 Aug; 10(4):515-21. PubMed ID: 23610455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kaplan-Meier Survival Analysis: Practical Insights for Clinicians.
    Gomes AP; Costa B; Marques R; Nunes V; Coelho C
    Acta Med Port; 2024 Apr; 37(4):280-285. PubMed ID: 38631048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A practical guide to understanding Kaplan-Meier curves.
    Rich JT; Neely JG; Paniello RC; Voelker CC; Nussenbaum B; Wang EW
    Otolaryngol Head Neck Surg; 2010 Sep; 143(3):331-6. PubMed ID: 20723767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidden Imputations and the Kaplan-Meier Estimator.
    Cole SR; Edwards JK; Naimi AI; Muñoz A
    Am J Epidemiol; 2020 Nov; 189(11):1408-1411. PubMed ID: 32412079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of the Cox model to the Fine-Gray model for survival analyses of re-fracture rates.
    Nolan EK; Chen HY
    Arch Osteoporos; 2020 Jun; 15(1):86. PubMed ID: 32519193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overestimation of the probability of death on peritoneal dialysis by the Kaplan-Meier method: advantages of a competing risks approach.
    Beuscart JB; Pagniez D; Boulanger E; Lessore de Sainte Foy C; Salleron J; Frimat L; Duhamel A
    BMC Nephrol; 2012 May; 13():31. PubMed ID: 22646159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kaplan-Meier Survival Analysis Overestimates the Risk of Revision Arthroplasty: A Meta-analysis.
    Lacny S; Wilson T; Clement F; Roberts DJ; Faris PD; Ghali WA; Marshall DA
    Clin Orthop Relat Res; 2015 Nov; 473(11):3431-42. PubMed ID: 25804881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
    Campigotto F; Weller E
    J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The analysis of competing events like cause-specific mortality--beware of the Kaplan-Meier method.
    Verduijn M; Grootendorst DC; Dekker FW; Jager KJ; le Cessie S
    Nephrol Dial Transplant; 2011 Jan; 26(1):56-61. PubMed ID: 21059831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Survival analysis with competing risks: estimating failure probability].
    Llorca J; Delgado-Rodríguez M
    Gac Sanit; 2004; 18(5):391-7. PubMed ID: 15498410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Introduction to the Analysis of Survival Data in the Presence of Competing Risks.
    Austin PC; Lee DS; Fine JP
    Circulation; 2016 Feb; 133(6):601-9. PubMed ID: 26858290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.